Who are CHONDRON's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 3ml-Rejuvinex, Platelet Rich Plasma (PRP), Leukocyte rich platelet rich plasma, Low-dose PRP, PCRA (Intermittent injection), SkinTE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chondron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CHONDRON — Competitive Intelligence Brief

CHONDRON (CHONDRON) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy. Area: Orthopedics / Regenerative Medicine.

phase 3 Autologous cell therapy Orthopedics / Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

CHONDRON (CHONDRON) — Sewon Cellontech Co., Ltd.. CHONDRON is an autologous chondrocyte-based cell therapy that regenerates cartilage tissue by implanting a patient's own expanded cartilage cells into damaged joint areas.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
CHONDRON TARGET	CHONDRON	Sewon Cellontech Co., Ltd.	phase 3	Autologous cell therapy
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
SkinTE	SkinTE	PolarityTE	marketed	Autologous cell therapy / Tissue-engineered product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy class)

Tetec AG · 2 drugs in this class
GC Cell Corporation · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class
Sewon Cellontech Co., Ltd. · 1 drug in this class
StemCyte, Inc. · 1 drug in this class
TiGenix n.v. · 1 drug in this class
Cook MyoSite · 1 drug in this class
UnicoCell Biomed CO. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHONDRON — Competitive Intelligence Brief. https://druglandscape.com/ci/chondron. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab